These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23737511)

  • 1. Posaconazole therapeutic drug monitoring in pediatric patients and young adults with cancer.
    Bernardo VA; Cross SJ; Crews KR; Flynn PM; Hoffman JM; Knapp KM; Pauley JL; Molinelli AR; Greene WL
    Ann Pharmacother; 2013; 47(7-8):976-83. PubMed ID: 23737511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed-release tablet and intravenous posaconazole.
    Bernardo V; Miles A; Fernandez AJ; Liverman R; Tippett A; Yildirim I
    Pediatr Transplant; 2020 Sep; 24(6):e13777. PubMed ID: 32639095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.
    Chen L; Wang Y; Zhang T; Li Y; Meng T; Liu L; Hao R; Dong Y
    BMC Infect Dis; 2018 Apr; 18(1):155. PubMed ID: 29609553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations.
    Märtson AG; Veringa A; van den Heuvel ER; Bakker M; Touw DJ; van der Werf TS; Span LFR; Alffenaar JC
    Mycoses; 2019 Aug; 62(8):698-705. PubMed ID: 31145490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring.
    Crombag MR; Huisman C; Kemper EM; Brüggemann RJ; Bijleveld YA
    Ther Drug Monit; 2012 Jun; 34(3):320-5. PubMed ID: 22561586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.
    Krishna G; Sansone-Parsons A; Martinho M; Kantesaria B; Pedicone L
    Antimicrob Agents Chemother; 2007 Mar; 51(3):812-8. PubMed ID: 17210771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia.
    Hummert SE; Green MR
    Ther Drug Monit; 2015 Aug; 37(4):508-11. PubMed ID: 25549205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience.
    Mathew S; Kussin ML; Liu D; Pozotrigo M; Seyboth B; Thackray J; Yan SQ; Hsu M; Cohen N; Seo SK
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e149-e151. PubMed ID: 28903522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posaconazole Therapeutic Drug Monitoring in a Regional Hospital Setting.
    Lindsay PJ; Bond SE; Norris R; Marriott DJ; Miyakis S
    Ther Drug Monit; 2016 Dec; 38(6):804-807. PubMed ID: 27548694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.
    Jancel T; Shaw PA; Hallahan CW; Kim T; Freeman AF; Holland SM; Penzak SR
    J Clin Pharm Ther; 2017 Feb; 42(1):75-79. PubMed ID: 27982447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience using intravenous posaconazole in paediatric and young adult oncology patients.
    Lambrix AA; Swanson HD; Pauley JL; Bragg AW; Carias DC; Bourque MS; Zhou Y; Cheng C; Greene WL; Maron G
    J Antimicrob Chemother; 2020 Dec; 75(12):3682-3687. PubMed ID: 32929484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents.
    Tragiannidis A; Herbrüggen H; Ahlmann M; Vasileiou E; Gastine S; Thorer H; Fröhlich B; Müller C; Groll AH
    J Antimicrob Chemother; 2019 Dec; 74(12):3573-3578. PubMed ID: 31504563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posaconazole plasma concentrations in critically ill patients.
    Ray J; Campbell L; Rudham S; Nguyen Q; Marriott D
    Ther Drug Monit; 2011 Aug; 33(4):387-92. PubMed ID: 21654350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
    Dolton MJ; Ray JE; Chen SC; Ng K; Pont L; McLachlan AJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5503-10. PubMed ID: 22890761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake.
    Eiden C; Meniane JC; Peyrière H; Eymard-Duvernay S; Le Falher G; Ceballos P; Fegueux N; Cociglio M; Reynes J; Hillaire-Buys D
    Eur J Clin Microbiol Infect Dis; 2012 Feb; 31(2):161-7. PubMed ID: 21611869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole oral dose and plasma levels in pediatric hematology-oncology patients.
    Vicenzi EB; Calore E; Decembrino N; Berger M; Perruccio K; Carraro F; Rossin S; Putti MC; Molinaro M; Tridello G; Cesaro S
    Eur J Haematol; 2018 Mar; 100(3):315-322. PubMed ID: 29240266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients.
    Matthias KR; Nix DE; Peloquin CA; Graham ML
    Ann Pharmacother; 2012 Sep; 46(9):e22. PubMed ID: 22872751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Intravenous Posaconazole Dosing and Pharmacokinetic Target Attainment in Pediatric Patients.
    Nickless JR; Bridger KE; Vora SB; Brothers AW
    J Pediatric Infect Dis Soc; 2019 Sep; 8(4):365-367. PubMed ID: 30299489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.
    Döring M; Müller C; Johann PD; Erbacher A; Kimmig A; Schwarze CP; Lang P; Handgretinger R; Müller I
    BMC Infect Dis; 2012 Oct; 12():263. PubMed ID: 23082876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
    Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.